NIKKEI 225
39,631.06 +47.98 (+0.12%) HANG SENG
17,718.61 +2.11 (+0.01%) CRUDE OIL
83.40 +0.02 (+0.02%) GOLD FUTURES
2,341.70 +2.80 (+0.12%) DOW
39,169.52 +50.66 (+0.13%) Bitcoin GBP
49,709.08 +116.88 (+0.24%)
VRTX Aug 2024 515.000 call
| Previous close | 2.3900 |
| Open | 5.6200 |
| Bid | 0.2000 |
| Ask | 6.8000 |
| Strike | 515.00 |
| Expiry date | 2024-08-02 |
| Day's range | 2.3800 - 5.6200 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
Business WireVertex to Announce Second Quarter 2024 Financial Results on August 1
BOSTON, July 01, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2024 Earnings Call."
- GuruFocus.com
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): EVP and CMO Carmen Bozic Sells 2,280 Shares
The transaction was executed at a price of $471.72 per share, as detailed in the SEC Filing. Following this sale, the insider now owns 30,099 shares of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a biotechnology firm focused on developing and commercializing therapies for the treatment of cystic fibrosis and other severe diseases.
ZacksVertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
